Skip to main content Skip to navigation
Hamburger Menu
Search icon
Country Selector Country Selector
Finland (English)
Profile Icon Profile Icon
Sign-in/Register UserName
Products

Solutions

Discover & Learn

Resources & Tools

Support

Search icon Search icon
Close Menu
      Alert Icon
      Purified Mouse Anti-TAF[II]135
      Product Details
      Down Arrow Up Arrow


      BD Transduction Laboratories™
      Human (QC Testing), Mouse (Tested in Development)
      Mouse IgG1
      Human TAF[II]135 aa. 454-565
      Western blot (Routinely Tested), Immunofluorescence (Tested During Development)
      135 kDa
      250 µg/ml
      AB_399441
      Aqueous buffered solution containing BSA, glycerol, and ≤0.09% sodium azide.
      RUO


      Preparation And Storage

      The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. Store undiluted at -20°C.
      Show More blue down arrow Show Less blue up arrow

      Recommended Assay Procedures

      Western blot: Please refer to http://www.bdbiosciences.com/pharmingen/protocols/Western_Blotting.shtml.

      Show More blue down arrow Show Less blue up arrow

      Product Notices

      1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
      2. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
      3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
      4. Source of all serum proteins is from USDA inspected abattoirs located in the United States.
      Show More blue down arrow Show Less blue up arrow
      612054 Rev. 1
      Antibody Details
      Down Arrow Up Arrow
      22/TAF[II]135

      Tightly associated factors (TAFs) play an essential role in transcriptional activation through their interaction with a variety of activators. TAF[II]135 (a.k.a. TAF[II]130) is a human homologue of Drosophila TAF[II]110, the first TAF shown to have coactivator activity. TAF[II]135 contains multiple glutamine-rich regions, as well as a coactivator domain (CAD). The glutamine-rich regions of TAF[II]135 facilitate interaction with Sp1 and CREB, which leads to enhancement of both Sp1- and CREB-mediated transcription. In addition, TAF[II]135 can potentiate transcriptional stimulation by AF-2 of the retinoic acid, thyroid hormone, and vitamine D3 receptors. However, TAF[II]135 does not interact with the AF-2s of  the estrogen and retinoid X receptors. Interestingly, TAF[II]135 enhancement of CREB transcriptional activity may be disrupted by expanded polyglutamine (CAG) repeats found in at least eight different neurodegenerative disorders. Thus, TAF[II]135 may have important coactivator activities in many different transcription-regulating cell signaling pathways, and interference of TAF[II]135 activity by CAG repeats may be a common mechanism of specific types of neuropathologies.

      612054 Rev. 1
      Format Details
      Down Arrow Up Arrow
      Purified
      Tissue culture supernatant is purified by either protein A/G or affinity purification methods. Both methods yield antibody in solution that is free of most other soluble proteins, lipids, etc. This format provides pure antibody that is suitable for a number of downstream applications including: secondary labeling for flow cytometry or microscopy, ELISA, Western blot, etc.
      Purified
      612054 Rev.1
      Citations & References
      Down Arrow Up Arrow

      Development References (4)

      1. Freiman RN, Albright SR, Chu LE, et al. Redundant role of tissue-selective TAF(II)105 in B lymphocytes. Mol Cell Biol. 2002; 22(18):6564-6572. (Clone-specific: Western blot). View Reference
      2. Mengus G, May M, Carre L, Chambon P, Davidson I. Human TAF(II)135 potentiates transcriptional activation by the AF-2s of the retinoic acid, vitamin D3, and thyroid hormone receptors in mammalian cells. Genes Dev. 1997; 11(11):1381-1395. (Biology). View Reference
      3. Saluja D, Vassallo MF, Tanese N. Distinct subdomains of human TAFII130 are required for interactions with glutamine-rich transcriptional activators. Mol Cell Biol. 1998; 18(10):5734-5743. (Biology). View Reference
      4. Shimohata T, Nakajima T, Yamada M. Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat Genet. 2000; 26(1):29-36. (Biology). View Reference
      View All (4) View Less
      612054 Rev. 1

      Please refer to Support Documents for Quality Certificates


      Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


      Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

      For Research Use Only. Not for use in diagnostic or therapeutic procedures.

      Website Feedback